ANXA2 and CTSS

Number of citations of the paper that reports this interaction (PubMedID 21963895)
1

Data Source:
BioGRID (two hybrid)

		ANXA2	CTSS
Description		annexin A2	cathepsin S
Image
GO Annotations	Cellular Component	Ruffle Extracellular Region Basement Membrane Extracellular Space Cell Nucleus Cytoplasm Lysosomal Membrane Endosome Early Endosome Lipid Droplet Cytosol Plasma Membrane Adherens Junction Cell Cortex Cell Surface Membrane Basolateral Plasma Membrane Extrinsic Component Of Plasma Membrane Midbody Late Endosome Membrane Vesicle Azurophil Granule Lumen Myelin Sheath Adaxonal Region Sarcolemma Melanosome Schmidt-Lanterman Incisure Macropinosome Membrane Raft Perinuclear Region Of Cytoplasm Collagen-containing Extracellular Matrix Extracellular Exosome AnxA2-p11 Complex PCSK9-AnxA2 Complex	Extracellular Region Extracellular Space Lysosome Late Endosome Endolysosome Lumen Lysosomal Lumen Intracellular Membrane-bounded Organelle Collagen-containing Extracellular Matrix Tertiary Granule Lumen Ficolin-1-rich Granule Lumen
	Molecular Function	Phosphatidylserine Binding Protease Binding RNA Binding Calcium Channel Activity Calcium Ion Binding Protein Binding Calcium-dependent Phospholipid Binding Phosphatidylinositol-4,5-bisphosphate Binding Cytoskeletal Protein Binding Rab GTPase Binding Phospholipase A2 Inhibitor Activity Identical Protein Binding S100 Protein Binding Virion Binding Calcium-dependent Protein Binding Cadherin Binding Involved In Cell-cell Adhesion Molecular Function Regulator	Fibronectin Binding Cysteine-type Endopeptidase Activity Collagen Binding Laminin Binding Proteoglycan Binding
	Biological Process	Angiogenesis Membrane Raft Assembly Positive Regulation Of Receptor Recycling Vesicle Budding From Membrane Body Fluid Secretion Viral Process Positive Regulation Of Vesicle Fusion Negative Regulation Of Low-density Lipoprotein Particle Receptor Catabolic Process Interleukin-12-mediated Signaling Pathway Osteoclast Development Negative Regulation Of Catalytic Activity Neutrophil Degranulation Positive Regulation Of Vacuole Organization Negative Regulation Of Development Of Symbiont Involved In Interaction With Host Regulation Of Cytosolic Calcium Ion Concentration Catabolism By Host Of Symbiont Protein Negative Regulation By Host Of Symbiont Molecular Function Calcium Ion Transmembrane Transport Response To Thyroid Hormone Cell-cell Adhesion Positive Regulation Of Low-density Lipoprotein Particle Clearance Positive Regulation Of Low-density Lipoprotein Particle Receptor Binding Positive Regulation Of Low-density Lipoprotein Receptor Activity Positive Regulation Of Receptor-mediated Endocytosis Involved In Cholesterol Transport	Toll-like Receptor Signaling Pathway Adaptive Immune Response Proteolysis Immune Response Response To Acidic PH Protein Processing Antigen Processing And Presentation Antigen Processing And Presentation Of Exogenous Peptide Antigen Via MHC Class II Extracellular Matrix Disassembly Collagen Catabolic Process Basement Membrane Disassembly Neutrophil Degranulation Antigen Processing And Presentation Of Peptide Antigen Proteolysis Involved In Cellular Protein Catabolic Process Cellular Response To Thyroid Hormone Stimulus Positive Regulation Of Cation Channel Activity
Pathways		Smooth Muscle Contraction Neutrophil degranulation Dissolution of Fibrin Clot Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	Endosomal/Vacuolar pathway Degradation of the extracellular matrix Degradation of the extracellular matrix Trafficking and processing of endosomal TLR Assembly of collagen fibrils and other multimeric structures MHC class II antigen presentation Neutrophil degranulation
Drugs		Tenecteplase Artenimol	Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide Morpholine-4-Carboxylic Acid [1-(2-Benzylsulfanyl-1-Formyl-Ethylcarbamoyl)-2-Phenyl-Ethyl]-Amide N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(BENZYLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-HYDROXYPHENYL)ETHYL]-L-ALANINAMIDE N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE N-[(1S)-1-{1-[(1R,3E)-1-ACETYLPENT-3-EN-1-YL]-1H-1,2,3-TRIAZOL-4-YL}-1,2-DIMETHYLPROPYL]BENZAMIDE (1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE 2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide
Diseases
GWAS		Asthma (age of onset) ( 31036433) Asthma (childhood onset) ( 31036433) Blood protein levels ( 30072576 28240269) Night sleep phenotypes ( 27126917) Type 2 diabetes ( 25102180)	Blood protein levels ( 30072576 29875488 28240269) Body mass index ( 26426971) Congenital left-sided heart lesions ( 26965164) Fat body mass ( 24064335) Rhegmatogenous retinal detachment ( 23585552)
Interacting Genes		43 interacting genes: ACTA1 APOH APP CCDC32 CD99 CDC42 CEACAM1 CTSB CTSS DYSF GRB2 HMGA1 LGALS13 LYPLA1 MAP3K4 MYOC NOD2 OGDH PHB PLA1A PLA2G4A PLAT PLG POT1 PRKCA PRKCB PTEN RPS2 S100A10 S100A4 S100A6 SMN1 SNX17 SOS1 SRC STAT6 TENT2 TERF1 TERT TP53 TRPV5 YWHAQ ZBTB4	9 interacting genes: ANXA2 BGLAP CST3 CST5 KNG1 PLCG1 SERPINB3 SERPINB4 SLPI
Entrez ID		302	1520
HPRD ID		01061	00292
Ensembl ID		ENSG00000182718	ENSG00000163131
Uniprot IDs		A0A024R5Z7 P07355	P25774
PDB IDs		1W7B 1XJL 2HYU 2HYV 2HYW 4DRW 4FTG 4HRH 5LPU 5LPX 5LQ0 5LQ2 5N7D 5N7F 5N7G	1BXF 1GLO 1MS6 1NPZ 1NQC 2C0Y 2F1G 2FQ9 2FRA 2FRQ 2FT2 2FUD 2FYE 2G6D 2G7Y 2H7J 2HH5 2HHN 2HXZ 2OP3 2R9M 2R9N 2R9O 3IEJ 3N3G 3N4C 3OVX 4P6E 4P6G 5QBU 5QBV 5QBW 5QBX 5QBY 5QBZ 5QC0 5QC1 5QC2 5QC3 5QC4 5QC5 5QC6 5QC7 5QC8 5QC9 5QCA 5QCB 5QCC 5QCD 5QCE 5QCF 5QCG 5QCH 5QCI 5QCJ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?